Xieqiao Yan

Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody–Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma

Xinan Sheng, Xieqiao Yan, Lin Wang et al. · Clinical Cancer Research · 2020 · 281 citations · Full text

Medicine, Oncology, Pharmacology +17

Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients

Bixia Tang, Xieqiao Yan, Xinan Sheng et al. · Journal of Hematology & Oncology · 2019 · 188 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Axitinib in Combination With Toripalimab, a Humanized Immunoglobulin G₄ Monoclonal Antibody Against Programmed Cell Death-1, in Patients With Metastatic Mucosal Melanoma: An Open-Label Phase IB Trial

Xinan Sheng, Xieqiao Yan, Zhihong Chi et al. · Journal of Clinical Oncology · 2019 · 169 citations · Full text

Medicine, Oncology, Pharmacology +17

Frequent Genetic Aberrations in the CDK4 Pathway in Acral Melanoma Indicate the Potential for CDK4/6 Inhibitors in Targeted Therapy

Yan Kong, Xinan Sheng, Xiaowen Wu et al. · Clinical Cancer Research · 2017 · 116 citations

Medicine, Molecular Genetics, Oncology +17

<i>MAPK</i> Pathway and <i>TERT</i> Promoter Gene Mutation Pattern and Its Prognostic Value in Melanoma Patients: A Retrospective Study of 2,793 Cases

Xue Bai, Yan Kong, Zhihong Chi et al. · Clinical Cancer Research · 2017 · 114 citations

Medicine, Molecular Genetics, Oncology +17